ea0029p1383 | Pituitary Clinical | ICEECE2012
Maione L.
, Garcia C.
, Kallel N.
, Bouchachi A.
, Maison P.
, Kamenicky P.
, Salenave S.
, Young J.
, Assayag P.
, Chanson P.
Context: The effects of cabergoline on cardiac valves have been extensively studied in Parkinsons disease and hyperprolactinemia but not in acromegaly, a condition at risk of cardiac valve abnormalities.Objective: We examined the prevalence of heart valve disease and regurgitation in a series of patients with acromegaly treated with cabergoline, by comparison with matched patients who had never received this drug.Design and s...